share_log

ImmunoPrecise Antibodies Analyst Ratings

ImmunoPrecise Antibodies Analyst Ratings

免疫精准抗体分析师评级
Benzinga ·  2023/09/18 06:53
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/18/2023 411.36% HC Wainwright & Co. → $9 Reiterates Buy → Buy
07/12/2023 411.36% HC Wainwright & Co. → $9 Reiterates Buy → Buy
07/11/2023 297.73% Benchmark → $7 Reiterates Speculative Buy → Speculative Buy
03/21/2023 297.73% Benchmark $12 → $7 Maintains Speculative Buy
03/17/2023 411.36% HC Wainwright & Co. → $9 Reiterates → Buy
12/02/2022 411.36% HC Wainwright & Co. → $9 Initiates Coverage On → Buy
10/25/2021 581.82% Benchmark → $12 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
09/18/2023 411.36% HC Wainwright公司 →$9 重申 购买→购买
07/12/2023 411.36% HC Wainwright公司 →$9 重申 购买→购买
07/11/2023 297.73% 基准 →$7 重申 投机性买入→投机性买入
03/21/2023 297.73% 基准 $12→$7 维护 投机性购买
03/17/2023 411.36% HC Wainwright公司 →$9 重申 →购买
12/02/2022 411.36% HC Wainwright公司 →$9 开始承保 →购买
2021年10月25日 581.82% 基准 →$12 开始承保 →购买

What is the target price for ImmunoPrecise Antibodies (IPA)?

免疫精制抗体(IPA)的目标价格是多少?

The latest price target for ImmunoPrecise Antibodies (NASDAQ: IPA) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $9.00 expecting IPA to rise to within 12 months (a possible 411.36% upside). 6 analyst firms have reported ratings in the last year.

免疫精制抗体(纳斯达克代码:IPA)的最新目标价是由HC Wainwright&Co.于2023年9月18日报告的。这家分析公司将目标价定为9美元,预计IPA将在12个月内上涨至(可能上涨411.36%)。6家分析公司在过去一年公布了评级。

What is the most recent analyst rating for ImmunoPrecise Antibodies (IPA)?

免疫纯化抗体(IPA)的最新分析师评级是多少?

The latest analyst rating for ImmunoPrecise Antibodies (NASDAQ: IPA) was provided by HC Wainwright & Co., and ImmunoPrecise Antibodies reiterated their buy rating.

对免疫精制抗体(纳斯达克代码:IPA)的最新分析师评级由HC Wainwright&Co.提供,免疫精制抗体重申其买入评级。

When is the next analyst rating going to be posted or updated for ImmunoPrecise Antibodies (IPA)?

下一次分析师评级将于何时发布或更新免疫精制抗体(IPA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunoPrecise Antibodies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunoPrecise Antibodies was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

分析师在进行了广泛的研究后得出股票评级,其中包括查阅公共财务报表,与免疫精准抗体的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。免疫精制抗体的上一次评级是在2023年9月18日提交的,所以你应该预计下一次评级将在2024年9月18日左右的某个时候提供。

Is the Analyst Rating ImmunoPrecise Antibodies (IPA) correct?

分析师对免疫精确度抗体(IPA)的评级正确吗?

While ratings are subjective and will change, the latest ImmunoPrecise Antibodies (IPA) rating was a reiterated with a price target of $0.00 to $9.00. The current price ImmunoPrecise Antibodies (IPA) is trading at is $1.76, which is within the analyst's predicted range.

虽然评级是主观的,并将发生变化,但最新的免疫精制抗体(IPA)评级被重申,目标价在0.00美元到9.00美元之间。目前免疫精制抗体(IPA)的交易价格为1.76美元,在分析师的预测范围内。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发